Edesa Biotech IncNASDAQ:EDSA
- LAST PRICE4.1600
- TODAY'S CHANGE (%)-0.3199 (-7.1408%)
- Bid / Lots3.0000/ 1
- Ask / Lots4.6600/ 2
- Open / Previous Close4.2600 / 4.4799
- Day Range
- 52 Week Range
- Volume8,124
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EDSA |
|---|---|---|
| 09:41 ET | 449 | 4.25 |
| 09:57 ET | 268 | 4.3 |
| 10:10 ET | 147 | 4.3341 |
| 10:19 ET | 300 | 4.4075 |
| 10:26 ET | 1042 | 4.6424 |
| 10:30 ET | 1080 | 4.64 |
| 12:43 ET | 101 | 4.3 |
| 01:42 ET | 2015 | 4.25 |
| 02:20 ET | 487 | 4.28 |
| 03:56 ET | 200 | 4.2104 |
| 03:57 ET | 400 | 4.2141 |
| 03:59 ET | 1023 | 4.16 |
Apr 11, 2024
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference, from 9:11AM ET on Thursday Apr 11, 2024 by Dow Jones
9:11AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 2, 2024
Edesa Biotech to Participate in Upcoming Investor Conferences, from 9:11AM ET on Tuesday Apr 02, 2024 by Dow Jones
9:11AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 21, 2024
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference, from 4:31PM ET on Thursday Mar 21, 2024 by Dow Jones
4:31PM ET on Thursday Mar 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Edesa Biotech Inc | 14.4M | -1.6x | --- |
Curative Biotechnology Inc | 14.5M | -2.7x | --- |
Microbot Medical Inc | 14.5M | -1.0x | --- |
NanoViricides Inc | 14.7M | -1.4x | --- |
NuCana PLC | 11.8M | -0.3x | --- |
Imunon Inc | 14.9M | -0.7x | --- |
Company Information
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.
Contact Information
- Headquarters
- 100 Spy CrtMARKHAM, ON, Canada L3R 5H6
- Phone
- 905-475-1234
- Fax
- 905-475-1234
Executives
- Independent Chairman of the Board
- Sean Macdonald
- President
- Michael Brooks
- Chief Executive Officer, Corporate Secretary, Director
- Pardeep Nijhawan
- Chief Financial Officer
- Stephen Lemieux
- Director
- Frank Oakes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.32 |
EPS | $-2.60 |
Book Value | $2.29 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
